Fonte: Lancet HIV. Unidade: FM
Assuntos: PESSOAS TRANSGÊNERO, HIV, PREVENÇÃO DE DOENÇAS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
ABNT
LANDOVITZ, Raphael J et al. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial. Lancet HIV, v. 10, n. 12, p. E767-E778, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/57947. Acesso em: 10 out. 2024.APA
Landovitz, R. J., Hanscom, B. S., Clement, M. E., Tran, H. V., Kallas, E. G., Magnus, M., et al. (2023). Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial. Lancet HIV, 10( 12), E767-E778. doi:10.1016/S2352-3018(23)00261-8NLM
Landovitz RJ, Hanscom BS, Clement ME, Tran HV, Kallas EG, Magnus M, Sued O, Sanchez J, Scott H, Eron JJ. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial [Internet]. Lancet HIV. 2023 ; 10( 12): E767-E778.[citado 2024 out. 10 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57947Vancouver
Landovitz RJ, Hanscom BS, Clement ME, Tran HV, Kallas EG, Magnus M, Sued O, Sanchez J, Scott H, Eron JJ. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial [Internet]. Lancet HIV. 2023 ; 10( 12): E767-E778.[citado 2024 out. 10 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57947